China’s CDE Explains Major Issues Around Conditional Approval Scheme
Executive Summary
China's conditional approval system, which is an accelerated pathway, is being increasingly used by pharma firms, but some thorny issues remain such as the impact on full approvals, the scheme’s relation to priority reviews and currently available therapies and deadlines for confirmatory studies. Staff from the country's Center for Drug Evaluation discussed various topics around the system in a recent article.
You may also be interested in...
Chinese Language Podcast: 出海新动向，数据出境，药监新政和后疫情的疫苗
The latest China biopharma trends, including Chinese biotech firms going overseas, post-COVID vaccine developments, new overseas data transfer standard contracts and developments at the Center for Drug Evaluation, are discussed in this Chinese-language podcast with Brian Yang in Beijing and Dexter Yan in Shanghai.
China Approves World’s First Bispecific IO Drug Amid PD-1/L1 Glut
Akeso’s PD-1/CTLA-4-targeting therapy cadonilimab has been the front-runner in the bispecific antibody field in China, leading about 50 other similar agents under development by domestic pharma firms. With a new conditional approval, it has also gained a head start over home-grown PD-1/L1 antibody rivals in the cervical cancer space.
3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.